Synact Pharma Aps
Clinical trials sponsored by Synact Pharma Aps, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to tame severe viral lung infections Results expected Aug 2027 (estimated)
-
New drug aims to tame severe viral lung infections
Disease control Recruiting nowThis study tests whether a daily pill called AP1189 can help hospitalized patients with breathing failure due to viruses like flu, RSV, or COVID-19. About 96 adults will receive either AP1189 or a placebo for 14 days, on top of usual care. The main goal is to see if the drug redu…
Phase 2 • Sponsor: SynAct Pharma Aps • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New pill aims to plug kidney leaks in rare disease
Disease control Recruiting nowThis study tests an experimental drug called AP1189 in people with a rare kidney condition called idiopathic membranous nephropathy, which causes severe protein leakage in urine. The trial includes 23 adults who are already on standard blood pressure medications. Participants wil…
Phase 2 • Sponsor: SynAct Pharma Aps • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New pill shows promise for early rheumatoid arthritis in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called AP1189 in 240 people with early rheumatoid arthritis who have not yet taken disease-modifying drugs. Participants receive one of three doses of AP1189 or a placebo, all alongside standard methotrexate, for 12 weeks. The goal is to see …
Phase 2 • Sponsor: SynAct Pharma Aps • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC